BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
31.35
+0.41 (+1.33%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close30.94
Open31.21
Bid0.00 x 0
Ask0.00 x 0
Day's Range31.10 - 31.37
52 Week Range25.50 - 35.41
Volume1,012,964
Avg. Volume376,239
Market Cap103.525B
Beta0.98
PE Ratio (TTM)12.12
EPS (TTM)2.59
Earnings DateN/A
Forward Dividend & Yield0.74 (2.39%)
Ex-Dividend Date2017-05-01
1y Target Est36.75
Trade prices are not sourced from all markets
  • Capital Cube2 days ago

    ETFs with exposure to Bayer AG : December 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Bayer AG Here are 5 ETFs with the largest exposure to BAYRY-US. Comparing the performance and risk of Bayer AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • EU regulators to warn Bayer about Monsanto bid: source
    Reuters8 days ago

    EU regulators to warn Bayer about Monsanto bid: source

    EU antitrust regulators are set to warn Bayer its planned purchase of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday, a move that would force Bayer to offer concessions to address the concerns. The $66 billion deal would make Bayer (BAYGn.DE) the world's largest pesticides and seeds company, an outcome already facing strong criticism from environmentalists and some farm groups. The European Commission is expected to send a charge sheet known as a statement of objections to the companies in the coming weeks, but a final decision has not yet been made, the person said.

  • EU regulators to warn Bayer about Monsanto bid -source
    Reuters8 days ago

    EU regulators to warn Bayer about Monsanto bid -source

    EU antitrust regulators are set to warn Bayer its planned purchase of U.S. seed maker Monsanto may hurt competition, a person familiar with the matter said on Friday, a move that would force Bayer to offer concessions to address the concerns. The $66 billion deal would make Bayer (BAYGn.DE) the world's largest pesticides and seeds company, an outcome already facing strong criticism from environmentalists and some farm groups. The European Commission is expected to send a charge sheet known as a statement of objections to the companies in the coming weeks, but a final decision has not yet been made, the person said.

  • Bayer to Face EU Objections to Monsanto Deal in Coming Days
    Bloomberg8 days ago

    Bayer to Face EU Objections to Monsanto Deal in Coming Days

    Bayer AG is set to get a so-called statement of objections cataloging potential reasons for the European Union’s antitrust regulator to block its proposed $66 billion takeover of Monsanto Co. as soon as ...

  • This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November
    Motley Fool10 days ago

    This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November

    Shareholders aren't seeing too clearly after this double-dose of news concerning lead drug Eylea.

  • Reuters11 days ago

    Jury orders Bayer, Johnson & Johnson to pay $28 million in Xarelto lawsuit

    The jury slapped the companies, which jointly developed the blockbuster drug, with $1.8 million in compensatory and $26 million in punitive damages, according to the couple's lawyer. The verdict marks the first trial loss in litigation over Xarelto. Bayer and J&J have won three previous cases in federal court.

  • Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit
    Reuters11 days ago

    Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit

    The jury slapped the companies, which jointly developed the blood thinner, with $1.8 million in compensatory and $26 million in punitive damages, according to the couple's lawyer. The verdict marks the first trial loss in litigation over Xarelto. Bayer and J&J have won three previous cases in federal court.

  • J&J, Bayer Ordered to Pay $28 Million in First Xarelto Loss
    Bloomberg11 days ago

    J&J, Bayer Ordered to Pay $28 Million in First Xarelto Loss

    Johnson & Johnson and Bayer AG are responsible for a woman’s injuries tied to the blood-thinning drug Xarelto and must pay more than $29 million in damages, jurors concluded in the companies’ first loss ...

  • Reuters15 days ago

    CFIUS clears Bayer's planned takeover of Monsanto

    Germany's Bayer said that the Committee on Foreign Investment in the United States had no national security concerns about the drugmaker's planned takeover of U.S. seeds group Monsanto, giving its go-ahead. ...

  • Market Realist17 days ago

    Nektar Therapeutics Sees Setbacks in Plans for Ciproflaxin DPI

    On November 16, 2017, the FDA's Antimicrobial Drugs Advisory Committee voted down the 14-day regimen and 28-day regimen of Nektar Therapeutics' ciprofloxacin DPI.

  • Brazil pushes back decision on Bayer-Monsanto tie-up
    Reuters24 days ago

    Brazil pushes back decision on Bayer-Monsanto tie-up

    Brazilian antitrust agency Cade on Wednesday extended its deadline to review the takeover of Monsanto Co (MON.N) by Bayer AG (BAYGn.DE) by 90 days to late March, potentially spoiling plans to wrap up the $66 billion (£49.60 billion) tie-up by the end of the year. Bayer and Monsanto declined to comment on the decision. Brazil is Monsanto's biggest market outside of the United States.

  • Motley Fool28 days ago

    Is Loxo Oncology's Deal With Bayer Bad News?

    Investors appear discouraged by the company's decision to license its lead product.

  • Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
    Zackslast month

    Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

    Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

  • Reuterslast month

    Bayer hires new blood to stem 'Amazon effect' in consumer health

    German drugmaker Bayer (BAYGn.DE) has hired the head of Nestle's (NESN.S) baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon (AMZN.O) and other online platforms. Bayer has appointed Nestle's Heiko Schipper, 48, to run the Consumer Health division as a group board member from March 1 next year, replacing Erica Mann, Bayer said in a statement on Wednesday. Bayer was caught off guard by the speed of U.S. consumers switching to online stores at the expense of established drugstores.

  • Reuterslast month

    Bayer hires new blood to stem 'Amazon effect' in consumer health

    German drugmaker Bayer has hired the head of Nestle's baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon and other online ...

  • Biotechs Sell Off In Droves — Are Investors Seeking Mergers?
    Investor's Business Dailylast month

    Biotechs Sell Off In Droves — Are Investors Seeking Mergers?

    Loxo's deal with Bayer had a bigger impact on the biotech sector than you'd expect, an industry observer said.

  • This Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal
    Investor's Business Dailylast month

    This Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal

    Loxo toppled Tuesday after agreeing to codevelop two cancer therapies with drug firm Bayer.

  • Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer
    Motley Foollast month

    Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer

    The global pharmaceutical giant has signed a deal that could be worth more than $1.5 billion to this clinical-stage cancer drug developer.

  • Reuterslast month

    Loxo signs lucrative cancer drug deal with Bayer, but shares fall

    Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover. Loxo caused a great deal of excitement at last year's biggest cancer meeting when its larotrectinib, which targets a specific genetic defect, led to significant tumor shrinkage in three quarters of patients with more than a dozen different tumor types, including several complete remissions . The deal, which includes Loxo's follow-up drug LOXO-195, gives Bayer entry into the fledgling field of drugs that attack cancer based on genetics rather than the organ where the disease originates.

  • Monsanto (MON) Premium Herbicide Declared Non-Carcinogenic
    Zackslast month

    Monsanto (MON) Premium Herbicide Declared Non-Carcinogenic

    The National Cancer Institute recently announced that Monsanto Company's (MON) Roundup herbicide is non-cancerous.

  • MarketWatchlast month

    Loxo announces $400 mln Bayer cancer partnership

    Loxo Oncology Inc. shares rose as much as 8% before declining nearly 3% in premarket trade on Tuesday after the company announced a $400 million partnership with Bayer AG to develop and commercialize two ...

  • Reuterslast month

    Loxo Oncology to develop, commercialize cancer drugs with Bayer

    U.S. drug developer Loxo Oncology Inc on Tuesday announced a deal with Bayer AG to develop and commercialize two of its cancer therapies and said it would receive $400 million upfront. Loxo is also eligible ...

  • Capital Cubelast month

    ETFs with exposure to Bayer AG : November 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Bayer AG Here are 5 ETFs with the largest exposure to BAYRY-US. Comparing the performance and risk of Bayer AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • From Bayer to Qualcomm, M&A Gets Costlier in the EU
    Bloomberglast month

    From Bayer to Qualcomm, M&A Gets Costlier in the EU

    If time is money, big M&A is getting a lot costlier in the European Union thanks to a tactic increasingly deployed by the bloc’s merger watchdogs in Brussels.

  • Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up
    Zackslast month

    Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up

    Regeneron reported impressive results in the third quarter driven by strong performance of Eylea.